JPWO2023079494A5 - - Google Patents
Info
- Publication number
- JPWO2023079494A5 JPWO2023079494A5 JP2024526616A JP2024526616A JPWO2023079494A5 JP WO2023079494 A5 JPWO2023079494 A5 JP WO2023079494A5 JP 2024526616 A JP2024526616 A JP 2024526616A JP 2024526616 A JP2024526616 A JP 2024526616A JP WO2023079494 A5 JPWO2023079494 A5 JP WO2023079494A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- day
- administered
- corticosteroid
- pharmaceutical combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275157P | 2021-11-03 | 2021-11-03 | |
| US63/275,157 | 2021-11-03 | ||
| US202163280791P | 2021-11-18 | 2021-11-18 | |
| US63/280,791 | 2021-11-18 | ||
| US202163288785P | 2021-12-13 | 2021-12-13 | |
| US63/288,785 | 2021-12-13 | ||
| US202263394726P | 2022-08-03 | 2022-08-03 | |
| US63/394,726 | 2022-08-03 | ||
| PCT/IB2022/060616 WO2023079494A1 (en) | 2021-11-03 | 2022-11-03 | Corticosteriod reduction in treatment with anti-cd38 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024540304A JP2024540304A (ja) | 2024-10-31 |
| JPWO2023079494A5 true JPWO2023079494A5 (https=) | 2025-11-11 |
| JP2024540304A5 JP2024540304A5 (https=) | 2025-11-11 |
Family
ID=84361138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526616A Pending JP2024540304A (ja) | 2021-11-03 | 2022-11-03 | 抗ｃｄ３８抗体による治療におけるコルチコステロイドの減少 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230136301A1 (https=) |
| EP (1) | EP4426435A1 (https=) |
| JP (1) | JP2024540304A (https=) |
| KR (1) | KR20240099411A (https=) |
| AU (1) | AU2022380155A1 (https=) |
| CA (1) | CA3237175A1 (https=) |
| CL (1) | CL2024001324A1 (https=) |
| IL (1) | IL312514A (https=) |
| JO (1) | JOP20240106A1 (https=) |
| MX (1) | MX2024005406A (https=) |
| WO (1) | WO2023079494A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025080911A1 (en) * | 2023-10-12 | 2025-04-17 | Janssen Biotech, Inc. | Methods for treating multiple myeloma comprising an anti-cd38 antibody combined with bortezomib, lenalidomide and dexamethasone |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| ES2532399T3 (es) | 2003-03-05 | 2015-03-26 | Halozyme, Inc. | Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden |
| DK2511297T3 (en) | 2004-02-06 | 2015-06-15 | Morphosys Ag | Human anti-CD38 antibodies and their applications |
| EP2567976B1 (en) | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| EP2860192B1 (en) | 2005-10-12 | 2017-09-27 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| EA033110B1 (ru) | 2012-04-11 | 2019-08-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы |
| ES2774976T3 (es) | 2013-04-29 | 2020-07-23 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| MX2017001079A (es) | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| SI3227339T1 (sl) | 2014-12-05 | 2022-02-28 | Memorial Sloan-Kettering Cancer Center | Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba |
| EA036379B1 (ru) | 2014-12-12 | 2020-11-02 | Блубёрд Био, Инк. | Химерные антигенные рецепторы к bcma |
| MX389805B (es) * | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| US10072088B2 (en) | 2015-08-17 | 2018-09-11 | Janssen Pharmaceutica, Nv | Anti-BCMA antibodies and uses thereof |
| DE102016211884A1 (de) | 2016-06-30 | 2018-01-04 | Zf Friedrichshafen Ag | Getriebe für ein Kraftfahrzeug, sowie Antriebsstrang für ein Kraftfahrzeug |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| EP4282877A3 (en) | 2016-08-10 | 2024-02-21 | Legend Biotech Ireland Limited | Chimeric antigen receptors targeting bcma and methods of use thereof |
| MA53122A (fr) | 2018-07-13 | 2021-05-19 | Genmab As | Variants d'anticorps cd38 et leurs utilisations |
| WO2020081881A2 (en) * | 2018-10-17 | 2020-04-23 | Janssen Biotech, Inc. | Method of providing subcutaneous administration of anti-cd38 antibodies |
| JP7303314B2 (ja) | 2019-01-18 | 2023-07-04 | ヤンセン バイオテツク，インコーポレーテツド | Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞 |
| US20200308297A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses |
-
2022
- 2022-11-03 US US17/979,874 patent/US20230136301A1/en not_active Abandoned
- 2022-11-03 AU AU2022380155A patent/AU2022380155A1/en active Pending
- 2022-11-03 CA CA3237175A patent/CA3237175A1/en active Pending
- 2022-11-03 US US17/980,149 patent/US20230134748A1/en active Pending
- 2022-11-03 MX MX2024005406A patent/MX2024005406A/es unknown
- 2022-11-03 KR KR1020247018523A patent/KR20240099411A/ko active Pending
- 2022-11-03 EP EP22809519.6A patent/EP4426435A1/en active Pending
- 2022-11-03 IL IL312514A patent/IL312514A/en unknown
- 2022-11-03 JP JP2024526616A patent/JP2024540304A/ja active Pending
- 2022-11-03 WO PCT/IB2022/060616 patent/WO2023079494A1/en not_active Ceased
-
2024
- 2024-04-30 CL CL2024001324A patent/CL2024001324A1/es unknown
- 2024-05-01 JO JOJO/P/2024/0106A patent/JOP20240106A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Robinson | Medical therapy of inflammatory bowel disease for the 21st century | |
| JP2025102775A5 (https=) | ||
| US20040038954A1 (en) | Method of treating inflammatory conditions with progesterone or progesterone analogs | |
| JP2006527193A5 (https=) | ||
| JP2008515890A5 (https=) | ||
| JP2021534201A5 (https=) | ||
| JP2024129140A5 (https=) | ||
| Marrani et al. | Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis: a case series | |
| JP2019514974A5 (https=) | ||
| JP2025072466A5 (https=) | ||
| Helfer et al. | Corticosteroids and adrenal suppression: characterising and avoiding the problem | |
| JPWO2020250915A5 (https=) | ||
| US6096731A (en) | Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation | |
| JPWO2023079494A5 (https=) | ||
| IL312514A (en) | Corticosteroid reduction in treatment with anti-cd38 antibodies | |
| IL312515A (en) | Bispecific cd16a binders | |
| JPWO2020038352A5 (https=) | ||
| JP2021505545A5 (https=) | ||
| US20100184732A1 (en) | Method of long-term treatment of graft-versus-host disease using topical active corticosteroids | |
| JPWO2023095510A5 (https=) | ||
| Yeo et al. | Treatment of Oral Lichen Planus with Intralesional Injection of Steroids | |
| US20040006053A1 (en) | Method of long-term treatment of Graft-Versus-Host Disease using topical active corticosteriods | |
| JPWO2023017252A5 (https=) | ||
| JPWO2023091887A5 (https=) | ||
| Grentner et al. | Successful Treatment of Bullous Pemphigoid with Lebrikizumab: A Case Report |